Science
Clinical Trials
BioAce is committed to the development of GMAR TTM therapies for cancer. Successful clinical trials are required to gain regulatory approval for new medications to advance patient care and may be required to support any approved products.
A list of existing BioAce clinical trials are below. For more information on BioAce clinical trials that may be recruiting, search “BioAce ” at www.clinicaltrials.gov.
Program
GMART-501
Phase
1
Sponsor
BioAce
Indication
The ALPHA Trial: Relapsed or refractory non-Hodgkin lymphoma (NHL)
Program
GMART-715
Phase
1
Sponsor
BioAce
Indication
The UNIVERSAL Trial: Relapsed or refractory multiple myeloma (MM)
Program
SKBT42
Phase
1
Sponsor
Servier
Indication
The PALL Trial: Relapsed or refractory Acute lymphoblastic leukemia (ALL) in pediatric patients
Program
SKBT42
Phase
1
Sponsor
Servier
Indication
The CALM Trial: Relapsed or refractory ALL in adults
BioAce ’s Expanded Access Policy
BioAce does not currently have any active Expanded Access protocols but we do have Clinical Trials open. These can be found on ClinicalTrials.gov.
Treating physicians may request information about Expanded Access for an BioAce therapy by contacting our clinical trials team by phone or email at:
- +1 (612) 924 1968
- clinicaltrials@bioacehealthterapeutics.com
BioAce will evaluate these requests individually and may provide physician requested Expanded Access for an BioAce therapy for patients with no other available therapies and for patients who are not eligible to participate in a current BioAce clinical trial. BioAce will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.
Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.